Diana De Oliveira-Gomes, Christian Guilliod, Ilan Vavilin, Ankeet Bhatt, Brendon Neuen, Jamie L W Kennedy, Manreet Kanwar, Megan Terek, Shashank S Sinha, Van-Khue Ton, Mitchell Psotka, Vanessa Blumer
{"title":"Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.","authors":"Diana De Oliveira-Gomes, Christian Guilliod, Ilan Vavilin, Ankeet Bhatt, Brendon Neuen, Jamie L W Kennedy, Manreet Kanwar, Megan Terek, Shashank S Sinha, Van-Khue Ton, Mitchell Psotka, Vanessa Blumer","doi":"10.1007/s11897-025-00706-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to elucidate the complex interplay between cardiogenic shock (CS) and renal function, detailing the mechanisms of kidney injury, identifying risk factors, and providing a framework for the diagnosis and management of acute kidney injury (AKI) in CS. We evaluate evidence supporting medical interventions, including vasopressors, inotropes, and mechanical circulatory support (MCS), in relation to renal outcomes.</p><p><strong>Recent findings: </strong>AKI affects up to 80% of patients with CS and is associated with higher mortality, especially when Renal Replacement Therapy (RRT) is required. Mechanisms include impaired perfusion, venous congestion, and systemic inflammation. Invasive hemodynamic assessment improves diagnostic accuracy. Continuous RRT is preferred in unstable patients, although early initiation has not been shown to provide a survival benefit. Emerging tools such as novel biomarkers and machine learning may aid in early detection and risk stratification. AKI in CS is common and multifactorial, with significant prognostic impact. Early recognition, hemodynamic optimization, and a multidisciplinary strategy remain essential. Future work should focus on individualized management approaches to improve outcomes.</p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"19"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-025-00706-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: This review aims to elucidate the complex interplay between cardiogenic shock (CS) and renal function, detailing the mechanisms of kidney injury, identifying risk factors, and providing a framework for the diagnosis and management of acute kidney injury (AKI) in CS. We evaluate evidence supporting medical interventions, including vasopressors, inotropes, and mechanical circulatory support (MCS), in relation to renal outcomes.
Recent findings: AKI affects up to 80% of patients with CS and is associated with higher mortality, especially when Renal Replacement Therapy (RRT) is required. Mechanisms include impaired perfusion, venous congestion, and systemic inflammation. Invasive hemodynamic assessment improves diagnostic accuracy. Continuous RRT is preferred in unstable patients, although early initiation has not been shown to provide a survival benefit. Emerging tools such as novel biomarkers and machine learning may aid in early detection and risk stratification. AKI in CS is common and multifactorial, with significant prognostic impact. Early recognition, hemodynamic optimization, and a multidisciplinary strategy remain essential. Future work should focus on individualized management approaches to improve outcomes.
期刊介绍:
This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.